Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: A systematic review and meta-analysis

British Journal of Sports Medicine

Volumn 49, Issue 10, 2015, Pages 657-672

  Laudy, Augustinus B M ^a,b   Bakker, Eric W P ^b   Rekers, Mark ^c   Moen, Maarten H ^d,e  

^a MEANDER MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Centrum Utrecht   (Netherlands)

^d Bergman Clinics   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); HEALTH CARE QUALITY; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; META ANALYSIS; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PATIENT SATISFACTION; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; INJECTIONS, INTRA-ARTICULAR; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; PATIENT SATISFACTION; PLATELET-RICH PLASMA; QUALITY ASSURANCE, HEALTH CARE; TREATMENT OUTCOME;

EID: 84928949295     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsports-2014-094036     Document Type: Review

References (56)

1. Lane NE, Brandt K, Hawker G, et al. OARSI-FDA initiative: Defining the disease state of osteoarthritis. Osteoarthritis Cartilage 2011;19: 478-2.
2. Suri P, Morgenroth DC, Hunter DJ. Epidemiology of osteoarthritis and associated comorbidities. PM&R 2012;4: S10-19.
3. Arden N, Nevitt MC. Osteoarthritis: Epidemiology. Best Prac Res Clin Rheumatol 2006;20: 3-25.
4. Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: New insights. Part 1: The disease and its risk factors. Ann Intern Med 2000;133: 635-46.
5. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58: 26-35.
6. Carr AJ, Robertsson O, Graves S, et al. Knee replacement. Lancet 2012;379: 1331-40.
7. ACR 2000 American College of Rheumatology Subcommittee on osteoarthritis guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. Arthritis Rheum 2000;43: 1905-15.
8. Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in woman. The Framingham Study. Ann Intern Med 1992;116: 535-9.
9. Zang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16: 137-62.
10. Bellamy N, Campbell J, Robinson V, et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Sys Rev 2006;19: CD005328.
11. Hepper CT, Halvorson JJ, Duncan ST, et al. The efficacy and duration of intra-Articular corticosteroid injection for knee osteoarthritis: A systematic review of level I studies. J Am Acad Orthop Surg 2009;17: 638-46.
12. Fortier LA, Barker JU, Strauss EJ, et al. The role of growth factors in cartilage repair. Clin Orthop Relat Res 2011;469: 2706-15.
13. Smelter E, Hochberg MC. New treatments for osteoarthritis. Curr Opin Rheumatol 2013;25: 310-16.
14. Mishra A, Harmom K, Woodall J, et al. Sports medicine applications of platelet rich plasma. Curr Pharm Biotechnol 2012;13: 1185-95.
15. Andia I, Sánchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol. Ther 2012;12: 7-22.
16. Kon E, Filardo G, Di Martino A, et al. Platelet-rich plasma (PRP) to treat sports injuries: Evidence to support its use. Knee Surg Sports Traumatol Arthrosc 2011;19: 516-27.
17. Cole BJ, Seroyer ST, Filardo G, et al. Platelet-rich plasma: Where are we now and where are we going. Sports Health 2010;2: 203-10.
18. Woodell-May JE, Pietrzak WS. Platelet-rich plasma in orthopaedics. In: Pietrzak WS, ed. Orthopedic biology and medicine: Muskuloskeletal tissue regeneration. Totawa, NJ: Humana Press, 2008: 547-68.
19. Jang S-J, Kim J-D, Cha S-S. Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis. Eur J Orthop Surg Traumatol 2013;23: 573-80.
20. Halpern B, Chaudhury S, Rodeo SA, et al. Clinical and MRI outcomes after platelet-rich plasma treatment for knee osteoarthritis. Clin J Sport Med 2013;23: 238-39.
21. Gobbi A, Karnatzikos G, Mahajan V, et al. Platelet-rich plasma treatment in symptomatic patients with knee osteoarthritis: Preliminary results in a group of active patients. Sports Health 2012;4: 162-72.
22. Sampson S, Reed M, Silvers H, et al. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: A pilot study. Am J Phys Med Rehabil 2010;89: 961-9.
23. Filardo G, Kon E, Buda R, et al. Platelet-rich plasma intra-Articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthosc 2011;19: 528-35.
24. Wang-Saegusa A, Cugat R, Ares O, et al. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-Term effects on function and quality of life. Arch Orthop Trauma Surg 2011;131: 311-17.
25. Kon E, Buda R, Filardo G, et al. Platelet-rich plasma: Intra-Articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010;18: 472-9.
26. Napolitano M, Matera S, Bossio M, et al. Autologous platelet gel for tissue regeneration in degenerative disorders of the knee. Blood Transfus 2012;10: 72-7.
27. Buhr M, Siekmann W. Intra-Articular injection of platelet rich plasma for cartilage repair [Intraartikuläre Injection von thrombozytenangereichertem Plasma zur Behandlung von Knorpelschäden]. Orthopädische Praxis 2009;45: 10-16.
28. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29: 1039-49.
29. Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24: 799-802.
30. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
31. Slavin RE. Best evidence synthesis: An intelligent alternative to meta-Analysis. J Clin Epidemiol 1995;48: 9-18.
32. Van Tulder M, Furlan A, Bombardier C, et al.; Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 2003;28: 1290-9.
33. Yang KGA, Raijmakers NJH, van Arkel ERA, et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008;16: 498-505.
34. Baltzer AW, Moser C, Jansen SA, et al. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009;17: 152-60.
35. Klatt BA, Lopez HL, Segal NA, et al. Treatment options in knee osteoarthritis: Total knee arthroplasty versus platelet-rich plasma. PM R 2011;3: 377-86.
36. Vaquerizo V, Placencia MA, Arribas I, et al. Comparison of intra-Articular injections of plasma rich in growth factors versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: A randomized controlled trail. Arthroscopy 2013;29: 1635-43.
37. Patel S, Dhillon MS, Aggerwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, double-blind, randomized trail. Am J Sports Med 2013;41: 356-4.
38. Filardo G, Kon E, Di Martino A, et al. Platelet-rich plasma versus hyaluronic acid to treat knee degenerative pathology: Study design and preliminary results of a randomized controlled trail. BMC Musculoskelet Disord 2012;13: 229.
39. Cerza F, Carnì S, Carcangiu A, et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-Articular infiltration in the treatment of gonarthrosis. Am J Sports Med 2012;40: 2822-7.
40. Sánchez M, Fiz N, Azofra J, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-Term treatment of symptomatic knee osteoarthritis. Arthroscopy 2012;28: 1070-8.
41. Say F, Gürler D, Yener K, et al. Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. Acta Chir Orthop Traumatol Cech 2013;80: 278-3.
42. Spaková T, Rosocha J, Lacko M, et al. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 2012;91: 411-17.
43. Li M, Zhang C, Ai Z, et al. Therapeutic effectiveness of intra-knee-Articular injection of platelet rich plasma on knee articular cartilage degeneration. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2011;25: 1192-6.
44. Filardo G, Kon E, Ruiz MTP, et al. Platelet-rich plasma intra-Articular injections for cartilage degeneration and osteoarthritis: Single-versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc 2012;20: 2082-91.
45. Kon E, Mandelbaum B, Buda R, et al. Platelet-rich plasma intra-Articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: From early degeneration to osteoarthritis. Arthroscopy 2011;27: 1490-501.
46. Mishra A, Harmon K, Woodall J, et al. Sports medicine applications of platelet rich plasma. Curr Pharm Biotech 2012;13: 1185-95.
47. Collins N, Misra D, Felson D, et al. Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS). Arthritis Care Res (Hoboken) 2011;63(Suppl 11): S208-28.
48. Davidson M, Keating J. Patient-reported outcome measures (PROMs): How should I interpret reports of measurement properties? A practical guide for clinicians and researchers who are not biostatisticians. Br J Sports Med 2014;48: 792-6.
49. Pham T, Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30: 1648-54.
50. Williams V, Piva S, Irrgang J, et al. Comparison of reliability and responsiveness of patient-reported clinical outcome measures in knee osteoarthritis rehabilitation. J Orthop Sports Phys Ther 2012;42: 716-23.
51. Petersson IF, Boegård T, Saxne T, et al. Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. Ann Rheum Dis 1997;56: 493-6.
52. Schiphof D, Boers M, Biersma-Zeinstra S. Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis. Ann Rheum Dis 2008;67: 1034-6.
53. Boswell S, Cole B, Sundman E, et al. Platelet rich plasma: A milieu of bioactive factors. Arthroscopy 2012;28: 429-39.
54. Foster T, Puskas B, Mandelbaum B, et al. Platelet-rich plasma: From basic science to clinical applications. Am J Sports Med 2009;37: 2259-72.
55. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Tromb Haemost 2004;91: 4-15.
56. Eppley B, Woodell J, Higgens J. Platelet quantification and growth factor analysis from platelet rich plasma: Implications for wound healing. Plast Reconstr Surg 2004;114: 1502-8.